Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain

SIMPLE SUMMARY: CAR T therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have been approved in Spain for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), given their favourable outcomes for overall survival and progression-free survival. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastos-Oreiro, Mariana, de las Heras, Ana, Presa, María, Casado, Miguel A., Pardo, Carlos, Martín-Escudero, Victoria, Sureda, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833685/
https://www.ncbi.nlm.nih.gov/pubmed/35158805
http://dx.doi.org/10.3390/cancers14030538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833685/
https://www.ncbi.nlm.nih.gov/pubmed/35158805
http://dx.doi.org/10.3390/cancers14030538

Ejemplares similares